297 related articles for article (PubMed ID: 27455450)
1. Inflammations mediators and circulating levels of matrix metalloproteinases: Biomarkers of diabetes in Tunisians metabolic syndrome patients.
Zayani Y; El Golli N; Zidi W; Guizani I; Boussairi S; Aloui S; Ayadi I; Ftouhi B; Feki M; Ben Romdhane N; Ben Sliman H; Allal-Elasmi M; Kaabachi N
Cytokine; 2016 Oct; 86():47-52. PubMed ID: 27455450
[TBL] [Abstract][Full Text] [Related]
2. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of plasma MMP-8, MMP-9 and TIMP-1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested case-control study.
Hoseini SM; Kalantari A; Afarideh M; Noshad S; Behdadnia A; Nakhjavani M; Esteghamati A
Metabolism; 2015 Apr; 64(4):527-38. PubMed ID: 25633268
[TBL] [Abstract][Full Text] [Related]
4. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
[TBL] [Abstract][Full Text] [Related]
5. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia.
Dogan A; Tuzun N; Turker Y; Akcay S; Kaya S; Ozaydin M
Coron Artery Dis; 2008 Dec; 19(8):559-63. PubMed ID: 19005290
[TBL] [Abstract][Full Text] [Related]
7. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
9. The adipokines and inflammatory marker in young type 2 diabetics with metabolic syndrome: A pilot study.
Wen MJ; Hsieh CH; Wu CZ; Hsiao FC; Hsia TL; Hung YJ; Pei D
Obes Res Clin Pract; 2013; 7(3):e206-10. PubMed ID: 23697589
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood levels of matrix and inflammatory mediators are elevated in Tunisian patients with acute coronary syndromes.
Zayani Y; Allal-Elasmi M; Jacob MP; Zidi W; Zaroui A; Feki M; Mourali S; Mechmech R; Kaabachi N
Clin Lab; 2013; 59(1-2):169-75. PubMed ID: 23505923
[TBL] [Abstract][Full Text] [Related]
11. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
12. Abnormal circulating levels of matrix metalloproteinases and their inhibitors in diabetes mellitus.
Zayani Y; Allal-Elasmi M; Jacob MP; Zidi W; Ftouhi B; Feki M; Slimane H; Kaabachi N
Clin Lab; 2012; 58(7-8):779-85. PubMed ID: 22997979
[TBL] [Abstract][Full Text] [Related]
13. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome.
Derosa G; D'Angelo A; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; Cicero AF
Heart Vessels; 2007 Nov; 22(6):361-70. PubMed ID: 18043992
[TBL] [Abstract][Full Text] [Related]
14. Association of Oxytocin with Glucose Intolerance and Inflammation Biomarkers in Metabolic Syndrome Patients with and without Prediabetes.
Akour A; Kasabri V; Bulatova N; Al Muhaissen S; Naffa R; Fahmawi H; Momani M; Zayed A; Bustanji Y
Rev Diabet Stud; 2018; 14(4):364-371. PubMed ID: 29590229
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes.
Vukasovic I; Tesija-Kuna A; Topic E; Supanc V; Demarin V; Petrovcic M
Clin Chem Lab Med; 2006; 44(4):428-34. PubMed ID: 16599837
[TBL] [Abstract][Full Text] [Related]
16. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H
Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633
[TBL] [Abstract][Full Text] [Related]
18. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
[TBL] [Abstract][Full Text] [Related]
19. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease.
Bolton CE; Stone MD; Edwards PH; Duckers JM; Evans WD; Shale DJ
Chron Respir Dis; 2009; 6(2):81-7. PubMed ID: 19411568
[TBL] [Abstract][Full Text] [Related]
20. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
